|
|
Other links at Articles > Allergy and Clinical Immunology |
| 1. |
New Anti-IL-5 Agent Cuts Need for Prednisone in Hypereosinophilic Syndrome
|
|
|
The investigational anti-interleukin-5 (anti-IL-5) monoclonal antibody mepolizumab (GlaxoSmithKline) caused a sharp drop in blood eosinophil count in nearly every patient with hypereosinophilic syndrome who received it. Mepolizumab also reduced the need for corticosteroids. Reuters Health Information
|
| 3. |
FDA Approvals: Moxatag, Welchol, Sular
|
|
|
The FDA has approved amoxicillin extended-release tablets (Moxatag), a new indication for colesevelam tablets (Welchol), and newly formulated nisoldipine extended-release tablets (Sular). Medscape Medical News
|
|
|